Anika Therapeutics (ANIK) Other financing activities (2012 - 2026)

Anika Therapeutics (ANIK) has 14 years of Other financing activities data on file, last reported at $1.7 million in Q1 2026.

• Other financing activities for Q1 2026 came in at $1.7 million, up 13.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 56.52% YoY), and the FY2025 annual result was $1.6 million, down 39.71% from the prior year.
• Other financing activities rose to $1.7 million in Q1 2026 per ANIK's latest filing, from $4000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $2.3 million in Q4 2024 and troughed at -$523000.0 in Q4 2023.
• A 5-year average of $398882.4 and a median of $66000.0 in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2025: Other financing activities sank 163.16% in 2023, then surged 6278.26% in 2025.
• A 5-year view of Other financing activities shows it stood at $828000.0 in 2022, then slumped by 163.16% to -$523000.0 in 2023, then soared by 549.14% to $2.3 million in 2024, then slumped by 99.83% to $4000.0 in 2025, then surged by 41350.0% to $1.7 million in 2026.
• Business Quant data shows ANIK's Other financing activities at $1.7 million in Q1 2026, $4000.0 in Q4 2025, and $13000.0 in Q3 2025.